Clinical Trial: Bispecific Antibodies Drive Improved Survival in Third-Line Therapy for RelapsedRefractory Diffuse Large B-Cell Lymphoma A Real-Word Study Before and After 2024 (China)

Posted On: 2026-10-12

China, Oct. 12 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Bispecific Antibodies Drive Improved Survival in Third-Line Therapy for RelapsedRefractory Diffuse Large B-Cell Lymphoma A Real-Word Study Before and After 2024'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133981

Registration Time: 2026/10/09

Type: Observational study

Primary Sponsor: The First Affiliated Hospital of Soochow University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=339932

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: Bispecific Antibodies Drive Improved Survival in Third-Line Therapy for RelapsedRefractory Diffuse Large B-Cell Lymphoma A Real-Word Study Before and After 2024 (China)